Alitretinoin
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl- 1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid |
|
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a601012 |
| Pregnancy cat. | D (US) |
| Legal status | Rx only |
| Routes | Topical, oral |
| Identifiers | |
| CAS number | 5300-03-8  |
| ATC code | D11AH04 L01XX22 |
| PubChem | CID 449171 |
| DrugBank | APRD00017 |
| ChemSpider | 395778 |
| UNII | 1UA8E65KDZ |
| ChEBI | CHEBI:50648 |
| ChEMBL | CHEMBL705 |
| Chemical data | |
| Formula | C20H28O2 |
| Mol. mass | 300.435 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Alitretinoin, or 9-cis-retinoic acid, is an antineoplastic agent developed by Ligand Pharmaceuticals. It is a first generation retinoid. Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
Contents |
[edit] Clinical uses
[edit] Kaposi’s sarcoma
In the United States, topical alitretinoin (trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. Alitretinoin is not indicated when systemic therapy against Kaposi's sarcoma is required.[1]
[edit] Chronic hand eczema
Under the trade name Toctino (marketed by Basilea, Switzerland) it has been granted prescription rights in the UK (08/09/2008) for oral use in chronic hand eczema.[2] In May 2009 the National Institute for Health and Clinical Excellence (NICE) issued preliminary guidance[3] on the use of Alitretinoin for the treatment of severe chronic hand eczema in adults. The recommendation stated that only patients with severe chronic hand eczema who are unresponsive to potent topical corticosteroids, oral immunosuppressants or phototherapy should receive the drug. Final NICE guidance is expected in August 2009.
[edit] References
- ^ "Panretin (Alitretinoin) Drug Information". RxList. November 21, 2000. http://www.rxlist.com/panretin-drug.htm. Retrieved 2009-01-14.
- ^ Ruzicka, Thomas, MD; Frederik Grønhøj Larsen, MD, PhD; Dorota Galewicz, MD; Attila Horváth, MD; Peter Jan Coenraads, MD; Kristian Thestrup-Pedersen, MD; Jean Paul Ortonne, MD; Christos C. Zouboulis, MD; Martin Harsch, PhD; Thomas C. Brown, PhD; Maurice Zultak, MD (2004). "Oral Alitretinoin (9-cis-Retinoic Acid) Therapy for Chronic Hand Dermatitis in Patients Refractory to Standard Therapy. Results of a Randomized, Double-blind, Placebo-Controlled, Multicenter Trial". Arch Dermatol 140 (12): 1453–1459. doi:10.1001/archderm.140.12.1453. PMID 15611422.
- ^ "NICE guidance documentation". http://www.nice.org.uk/guidance/index.jsp?action=byID&o=12035.
[edit] External links
- Prescribing Information (revised February 2007). Retrieved on 01-30-08.
|
|||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 |
This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
